Can a common gout drug ease a tough type of heart failure?
NCT ID NCT05637398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether colchicine, an anti-inflammatory drug, can lower inflammation in people with a specific type of heart failure called HFpEF. 42 adults with heart failure symptoms and signs of inflammation took part. The goal was to see if colchicine could reduce markers of inflammation and improve heart function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLCHICINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A Shchendrygina
Moscow, 119415, Russia
-
Anastasia Shchendrygina
Moscow, 119415, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a decades-old arthritis drug protect dialysis patients' hearts and veins?
- Exercise as medicine: can a tailored workout program reduce hospital visits for heart failure patients?
- Tailored HIIT may boost fitness in stubborn heart failure
- Old gout drug may keep heart in rhythm after valve surgery
- AI-Powered patch could replace ultrasound for heart checkups
- New hope for heart patients: drug may cut death risk after valve surgery